Baird Reiterates Outperform Rating on Axsome Therapeutics (AXSM)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
Axsome Therapeutics (AXSM) PT Raised to $124 at Cantor Fitzgerald
December 31, 2024 6:37 AM UTCCantor Fitzgerald analyst Charles C. Duncan raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $124.00 (from $121.00) while maintaining a Overweight rating.
The analyst comments "AXSM announced topline results from the P3 ACCORD-2 and ADVANCE-2 trials of AXS-05 (approved as AUVELITY in MDD) in Alz Dis agitation (ADA). We acknowledge todays results may be considered mixed, as ADVANCE-2 did not reach stat. sig. (AXSM trading -8% vs. -1% with the XBI). However, we believe that the clear ACCORD-2 data, combined with previously PR'd ADVANCE-1 data... More
Axsome Therapeutics (AXSM) PT Lowered to $122 at Mizuho
December 31, 2024 6:09 AM UTCMizuho analyst Graig Suvannavejh lowered the price target on Axsome Therapeutics (NASDAQ: AXSM) to $122.00 (from $124.00) while maintaining a Outperform rating.
The analyst comments "Yesterday, AXSM announced highly anticipated P3 data for lead asset AXS-05 in Alzheimer's disease agitation/ADA, a significant, potential... More
